⚕️💊 QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults
Wednesday, 18 January 2023 10:22.AM
- QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine.
- AbbVie is the only pharmaceutical company to offer three treatments across the full spectrum of migraine to help patients living with this debilitating disease. -
AbbVie announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of episodic migraine (< 15 migraine days per month) in adults.1 QULIPTA, the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) preventive treatment, marks the latest innovation in AbbVie's migraine portfolio to support Canadians impacted by migraine.
"Migraine is one of the leading causes of disability in Canada and impacts a person's ability to function and perform their daily routines," says Dr. Elizabeth Leroux, Founder and Chair, Migraine Canada. "People with migraine face incredible challenges managing a debilitating neurological condition that others cannot see or truly understand. Migraine Canada welcomes the approval of QULIPTA for Canadians who will now have an opportunity to experience a new treatment that will help prevent and manage episodic migraine appropriately and take control of their migraine attacks before they even start."
The approval is supported by data from a robust clinical program evaluating the efficacy, safety and tolerability of QULIPTA in nearly 2,000 patients who experienced 4 to 14 migraine days per month. QULIPTA demonstrated statistically significant, clinically meaningful, rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4. 1
"AbbVie is committed to bringing new innovative treatments to address the needs of Canadians living with migraine," says Tracey Ramsay, Vice President and General Manager, AbbVie Canada. "With the approval of QULIPTA for the preventive treatment of episodic migraine, AbbVie has expanded on our support to those living with migraine given the legacy of BOTOX® for the treatment of chronic migraine, and recently approved UBRELVY® for acute treatment of migraine. AbbVie is proud to partner with the migraine community to advance treatment and care for people living with this neurological disease."
SOURCE: AbbVie Canada
-
Related materials:
- 15-Nov-2023 08:00 AM ONTARIO JOBS 🧑🔎🥘☕ 25,000 Jobs by 2025: Food and Beverage Ontario Launches Recruitment Campaign for The Province's Food and Beverage Processing Industry Workforce 💵
- 29-Jul-2023 02:21 PM TORONTO ☕ World-Renowned Japanese Coffee Brand % Arabica Opens First Downtown Toronto Location
- 29-Jul-2023 10:21 AM 🌳🌿💵 Eating More Plants Could Save You 14% on Groceries, Says Report
- 28-Jul-2023 04:21 PM TORONTO 🍲🥘✈️ Toronto Pearson Airport Welcomes Osmow's Authentic Mediterranean and Middle Eastern Restaurant to Terminal 1
- 21-Jul-2023 04:06 PM 🌳🌿🧀 Get Ready to Crumble: Daiya Foods Launches Two New Plant-Based Cheeses!
- 19-Jul-2023 04:23 PM 🍲🥘 Nearly All Canadians (91%) Identify Cooking From Scratch as a Way to Save on Groceries
- 18-Jul-2023 02:33 PM 🌾🌽 Government Of Canada Announces Two New Living Labs in Quebec
- 15-Feb-2023 04:22 PM ⚕️💊 Novartis Partners With Network of Secondary Prevention Clinics to Redefine the Standard of Care for Cardiovascular Disease Prevention and Treatment in Ontario
- 15-Feb-2023 02:23 PM ⚕️💊 Shoppers Drug Mart Puts Sexual Wellness in Customer's Hands With Online Launch of Canada's Top-Rated Products
- 08-Feb-2023 02:23 PM ⚕️🧠 Canadian Front-Line Mental Health Professionals Share Timely Insights on the Stresses, Scars and Opportunities Emerging from the Pandemic